Disclosures: Wen Zhang: Nothing to Disclose, Wei Chen: Nothing to Disclose, Yameng Sun: Nothing to Disclose, Ning Zhang: Nothing to Disclose, Hong Li: Nothing to Disclose, Wenyue Wu: Nothing to Disclose, Xiaoning Wu: Nothing to Disclose, Xuzhen Yan: Nothing to Disclose, Qi Han: Nothing to Disclose, Aiting Yang: Nothing to Disclose, Hong You: Nothing to Disclose 2041 LYSYL OXIDASE INHIBITOR AMELIORATES ECM CROSS-LINKING AND INFILTRATING MACROPHAGES IN HEPATOCELLULAR CARCINOMA WITH FIBROSIS/ CIRRHOTIC BACKGROUND Basundhara Das 1 Sachin Sharma 2 Maryam Shaikh 3 Bornika Roy 1 Sampa Ghose 4 Subhrajit Biswas 1 , 1 Amity Centre for Liver Research (ACLR), Amity Institute of Molecular Medicine & Stem Cell Research, 2 Division of Gastroenterology and Hepatology, Department of Medicine, UCSF, USA, 3 Heersink school of Medicine, University of Alabama, Birmingham, USA, 4 Department of Medical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi, India Background: During onset of hepatocellular carcinoma (HCC) in fibrosis/ cirrhotic microenvironment, secretion of extracellular matrix (ECM) proteins from hepatic stellate cells (HSCs) and cross-linking of ECM proteins by Lysyl Oxidase (LOX) are associated with endothelial cells (ECs) and infiltration of bone marrow derived macrophages
Iram, S
In the present study, we found the augment of hepatocyte oxidation and premature aging, along with the decrease of plasm IGF-1 level in patients with liver fibrosis and CCl 4 -induced liver injury rat models
The M105I mutation alters the preferential plasma membrane-bound distribution of -SNAP in vivo To explore whether the reduction in protein-lipid interaction of the -SNAP M105I mutant, as suggested by in silico studies and observed in in vitro experiments, was also present in vivo, we analyzed the subcellular distribution of -SNAP in the brain of WT and hyh mutant mice
